ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Phase A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to discover Risk-free dosing regimen. Extra contributors are going to be enrolled for the recognized monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 will probably be offered as "increase-on" therapy. In Section C, part